Abiomed Inc: (NASD: ABMD)

$21.72

-0.11 (-0.50%)

Volume 609,245

May 23 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		21.39 - 21.78
	
		52wk Low - High
		11.80 - 24.93
	
		Previous Close
		21.83
	
		Avg. Volume
		441,434
	
		Industry
		MED INSTRUMENTS
	
		Market Cap
		841.72 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.27
	
		PE (Forward)
		59.92
	
		Current Year Est.
		0.36
	
		Quarterly Earnings ESP 
		-14.29%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		121 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 03/21/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            59.92
                        
                            PEG Ratio
                            2.81
                        
                            Current Year Est.
                            0.36
                        
                            Current Quarter Estimate
                            0.07
                        
                            Most Accurate Estimate
                            0.06
                        
                            Earnings ESP 
                            -14.29%
                        
                            Next Earnings Report Date
                            08-08-2013
                        
                            EPS Last Year
                            0.37
                        
                            Expected Earnings Growth
                            21.33%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Abiomed, Inc. is a developer, manufacturer and marketer of medical products designed to safely and effectively assist or replace the pumping function of the failing heart. The company currently manufactures and sells the BVS-5000, a temporary heart assist device, which is approved by the U.S. Food and Drug Administration for the temporary treatment of all patients with failing but potentially recoverable hearts. The company is also engaged in research and development relating to other devices to support the pumping function of the heart.   
Full ABMD Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ABMD Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (03/2014)	Next Year (03/2015)
Average Estimate	0.07	0.08	0.36	0.63
Number of Estimates	5	5	7	3
Low Estimate	0.04	0.06	0.31	0.57
High Estimate	0.12	0.12	0.50	NA
Year Ago EPS	0.08	0.13	0.37	0.36
EPS Growth	-12.50%	-35.38%	-1.54%	72.03%

More ABMD Estimates

Average Earnings Estimates for ABMD

EPS Growth for ABMD

Industry Analysis

Name	Symbol	Previous Close
ABIOMED INC	ABMD	21.83
NATUS MEDICAL	BABY	14.05
CRYOLIFE INC	CRY	6.31
DELCATH SYS INC	DCTH	0.42
GLOBUS MEDICAL	GMED	15.29
HEARTWARE INTL	HTWR	92.81
MELA SCIENCES	MELA	1.08
OXYSURE SYSTEMS	OXYS	0.81
PACIFIC BIOSCI	PACB	2.45
SUNSHINE HEART	SSH	5.88

Sector:Medical>> Industry:MED INSTRUMENTS

COMPARE TICKER vs. Its Peers

Zacks Commentary

HMA Matches Earnings, Misses Rev Est.

May 06, 2013

Thoratec Misses Earnings and Rev Est

May 06, 2013

Zacks #1 Rank Additions for Monday

May 06, 2013

MWI Vet Earnings Beat, Sales Miss

May 03, 2013

Abiomed Earnings Beat in 4Q

May 03, 2013

Masimo Matches Earnings Est.

May 03, 2013

Dismal Earnings Miss by Omnicell

May 03, 2013

Merge 1Q13: Loss Widens; Meets Est

May 02, 2013

More ABMD Zacks Commentary

Financials

EPS TTM	0.37
Sales	158
Net Income	15
Price/Earnings	59.00
Price/Book	6.14
Price/Cash Flow	55.25
Price/Sales	5.32

More ABMD Financials

News

Short-term Underperformance Detected in Shares of Natus Medical in the Health Care Equipment Industry (BABY, ABMD, MAKO, ARAY, HOLX) - Financial News Network Online - News Corner

May 23, 2013

Abiomed to Present at Deutsche Bank 38th Annual Health Care Conference - Globenewswire

May 22, 2013

Short-term Underperformance Detected in Shares of ABIOMED in the Health Care Equipment Industry (ABMD, EW, DXCM, WMGI, BCR) - Financial News Network Online - News Corner

May 22, 2013

53.8% Return Seen to Date on SmarTrend ABIOMED Call (ABMD) - Comtex Smartrend(R)

May 21, 2013

Analysis of Relative Performance in the Health Care Equipment Industry for Shares of Thoratec (THOR, HTWR, EW, ABMD, CFN) - Financial News Network Online - News Corner

May 21, 2013

Abiomed to Present at UBS Global Health Care Conference - Globenewswire

May 17, 2013

BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector - GuruFocus

May 14, 2013

J-- SERVICE AGREEMENT COVERAGE - ABIOMED IMPELLA AIC SYSTEM - Fedbizopps

May 14, 2013

See All News Stories on ABMD

Broker Recommendations

Current ABR	2.18
ABR (Last Week)	2.18
# of recs in ABR	11
Average Target Price	20.75
Industry Rank by ABR	121 out of 265
Rank in Industry	10 out of 54

More ABMD Broker Recommendations

Day Low - High	21.39 - 21.78
52wk Low - High	11.80 - 24.93
Previous Close	21.83
Avg. Volume	441,434
Industry	MED INSTRUMENTS
Market Cap	841.72 M
Div - Yield	0.00 - 0.00
Beta	1.27
PE (Forward)	59.92
Current Year Est.	0.36
Quarterly Earnings ESP	-14.29%

PE (Forward)	59.92
PEG Ratio	2.81
Current Year Est.	0.36
Current Quarter Estimate	0.07
Most Accurate Estimate	0.06
Earnings ESP	-14.29%
Next Earnings Report Date	08-08-2013
EPS Last Year	0.37
Expected Earnings Growth	21.33%

Username: Password:

Remember me [?]

Abiomed Inc: (NASD: ABMD)

$21.72

-0.11 (-0.50%)

Volume 609,245

May 23 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED INSTRUMENTS

Zacks Commentary

Financials

News

Broker Recommendations